Name: Q&A with Lunglife AI's CEO, Paul Pagano
Uploaded: 2022-09-26T06:43:18.895053+00:00
Duration: 1886 s
Channel: Vox Markets

Vox Markets

Lung cancer is an awful disease which annually kills around 1.8m people worldwide. Worse still, around 40% of those patients deemed at risk from indeterminant lung nodules are diagnosed incorrectly using CT scans.

In this fascinating interview, CEO Paul Pagano explains why Lunglife AI‘s ground-breaking technology could literally transform the early diagnosis of this terrible condition.

What the science does & how it works. Start
Accuracy of the LungLB test vs existing standard of care. 03:03
Advantages of using Circulating Tumour Cells. 03:51
Size of addressable market. 06:15
Progress of 425 person validation trial. 09:04
Is FDA approval required? 11:27 
Difference between validation & utility studies. 12:22 
Significance of New York Clinical Laboratory Evaluation Programme permit. 14:41
Timeline to 1st revenues. 16:01 
International opportunities. 17:41
Funding runway. 18:57
Future newsflow. 20:40

Lung cancer is an awful disease which annually kills around 1.8m people worldwide. Worse still, around 40% of those patients deemed at risk from indeterminant lung nodules are diagnosed incorrectly using CT scans.In this fascinating interview, CEO Paul Pagano explains why Lunglife AI‘s ground-breaking technology could literally transform the early diagnosis of this terrible condition.What the science does &amp; how it works. Start Accuracy of the LungLB test vs existing standard of care. 03:03 Advantages of using Circulating Tumour Cells. 03:51 Size of addressable market. 06:15 Progress of 425 person validation trial. 09:04 Is FDA approval required? 11:27 Difference between validation &amp; utility studies. 12:22 Significance of New York Clinical Laboratory Evaluation Programme permit. 14:41 Timeline to 1st revenues. 16:01 International opportunities. 17:41 Funding runway. 18:57 Future newsflow. 20:40

What the science does & how it works

Accuracy of the LungLB test vs existing standard of care

Advantages of using Circulating Tumour Cells

Size of addressable market

Progress of 425 person validation trial

Is FDA approval required?

Difference between validation & utility studies

Significance of New York Clinical Laboratory Evaluation Programme permit.

Timeline to 1st revenues

International opportunities

Funding runway

Future newsflow

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/011/005011/video_GygH93Q.mp4